San Jose, CA, United States of America

Gerrit Klaemer

This inventor holds 1 USPTO granted patent. Top assignee: Ilypsa, Inc.. Active years: 2009.


Average Co-Inventor Count = 13.0

ph-index = 1

Forward Citations = 13(Granted Patents)


Company Filing History:


Years Active: 2009

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Gerrit Klaemer: Innovator in Anion-Binding Polymers

Introduction

Gerrit Klaemer is a notable inventor based in San Jose, CA. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of hyperphosphatemia. His innovative work focuses on the development of anion-binding polymers that have the potential to improve patient outcomes.

Latest Patents

Gerrit Klaemer holds a patent for the "Treatment of hyperphosphatemia using crosslinked small molecule amine polymers." This patent describes anion-binding polymers that exhibit low swelling properties and a specific pore volume distribution. These characteristics ensure that a fraction of the polymer remains unavailable for non-interacting solutes above a certain molecular weight of the target ion. Additionally, the polymers are designed to minimize ion-binding interference, which is crucial for their effectiveness in gastrointestinal applications. The patent also covers pharmaceutical compositions, methods of use, and related kits.

Career Highlights

Klaemer's career is marked by his role at Ilypsa, Inc., where he has been instrumental in advancing research and development in polymer technology. His innovative approach has led to the creation of effective treatments that address critical health issues.

Collaborations

Gerrit Klaemer has collaborated with notable colleagues, including Eric F. Connor and Dominique Charmot. These partnerships have fostered a collaborative environment that enhances the development of groundbreaking solutions in the pharmaceutical industry.

Conclusion

Gerrit Klaemer's contributions to the field of anion-binding polymers represent a significant advancement in the treatment of hyperphosphatemia. His innovative work continues to pave the way for new therapeutic options that can improve patient care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…